Euroapi Company Header Euroapi Company Header

X

Find Drugs in Development News & Deals for VIC 1911

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

VIC-1911 is a novel, highly selective, and orally active small molecular inhibitor of aurora kinase A (AURKA). AURKA gene amplification/overexpression is reported in multiple tumors, including NSCLC.


Lead Product(s): VIC-1911,Sotorasib

Therapeutic Area: Oncology Product Name: VIC-1911

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

VIC-1911 is a novel and orally active inhibitor of Aurora A kinase, a key regulator in mitotic cell division and sirolimus specifically designed to substantially reduce GVHD, facilitate full potential of leukemia effect, and maximize GVHD-free, relapse-free survival.


Lead Product(s): VIC-1911,Cyclophosphamide,Sirolimus

Therapeutic Area: Immunology Product Name: VIC-1911

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: University of Minnesota Medical School

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 26, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Two Phase-1 clinical studies have been conducted in the US and Europe by Taiho. VITRAC obtained an exclusive and global development and commercialization rights for TAS-119, and its IND has been successfully transferred to VITRAC in the US with a new code name, VIC-1911.


Lead Product(s): VIC-1911

Therapeutic Area: Oncology Product Name: VIC-1911

Highest Development Status: Phase IProduct Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY